Diz osteoartrit hastalarında nötrofil/lenfosit oranı, trombosit/lenfosit oranı ve ortalama trombosit hacminin değerlendirilmesi

Kaynakça (13)

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26-35
2. Felson DT. Clinical practice. Osteoarthritis of the knee. N Engl J Med. 2006;354:841-8
3. Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA et al. Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med. 2000;133:726-37
4. Blagojevic M, Jinks C, Jeffery A, Jordan KP. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2010;18:24-33
5. Zhuo Q, Yang W, Chen J, Wang Y. Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol. 2012;8:729-37
6. Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom TM et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12:580-92
7. Kuyumcu ME, Yesil Y, Oztürk ZA, Kizilarslanoğlu C, Etgül S, Halil M et al. The evaluation of neutrophil-lymphocyte ratio in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;34:69-74
8. Boyraz I, Koç B, Boyacı A, Tutoğlu A, Sarman H, Ozkan H. Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spondylitis that are treating with anti-TNF. Int J Clin Exp Med. 2014;7:2912-15
9. Kilincalp S, Çoban Ş, Akinci H, Hamamcı M, Karaahmet F, Coşkun Y et al. Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma. Eur J Cancer Prev. 2015;24:328-33
10. Kellgren JH, Lawrance JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16:494-502
11. Akopuz A, Turan V, Ozcan A, Kopuz Y, Toz E, Kurt S. A novel marker for the assessment of the treatment result in pelvic inflammatory disease. Minerva Ginecol. 2016;68:117-23
12. Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther. 2013;14:469-75
13. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer